Академический Документы
Профессиональный Документы
Культура Документы
Drug Carriers
By: Yue Yu
BioE@UIC
Chitosan Nanoparticles (CSNPs)
A Promising Drug Delivery System
Stability in nano-scale
Low toxicity
Excellent biocompatibility
Simple and mild preparation method
Versatile routes of administration
Sub-micron size for non-invasive route
Note: The most popular “non-invasive route” is the “mucosal” routes of
administration, such as oral, nasal, and ocular mucosa, which will be
facilitated by chitosan absorption enhancing effect.
Eur. J. Pharm. Sci. 4: 23-31
Why Nano?
Conventional
Novel Dosage Forms
Dosage Forms
Some technical
limitations including
Only a small amount of poor reproducibility
Liposome and stability, and low
administered dose reaches
the target site, while the drug entrapment
majority of the drug Sub efficiency
distributes throughout the micron Better reproducibility
rest of the body in DDS and stability profiles,
accordance with its Polymeric high efficiency to
physicochemical and NPs reach the target site,
biochemical properties. and targeted drug
delivery with optimal
drug release profiles
Kumar and Banker, 2001
Intro –NPs in Pharmaceuitics
Nanoparticles: Solid colloidal particles with diameters ranging
from 1-1000 nm. They can be used therapeutically as adjuvant in
drug carriers in which the active ingredient is dissolved, entrapped,
encapsulated, adsorbed or chemically attached. Polymers used to
form NPs can be both synthetic and natural polymers. There are
two types of NPs: “nanospheres” and “nanocapsules”. Nanospheres
have a monolithic-type structure (matrix) in which drugs are
dispersed or adsorbed onto their surfaces. Nanocapsules exhibit a
membrane-wall structure and drugs are entrapped in the core or
adsorbed onto their exterior.
Non-toxic Non-toxic
Peroral administration
Ocular administration
Delivery of vaccines
Fu Chen, 2007
TMC precipitation efficacy as a function of TPP concentration
(TMC 2 mg/ml, TPP 0.1–0.9 mg/ml). Data shown are the
mean±S.D. (n = 3). TMC33 (▲) and TMC37 (■).
Fu Chen, 2007
Fu Chen, 2007
Fu Chen, 2007
The figure below compares the permeate efficiency
of modified and non-modified TMC nanoparticles,
alginate modified TMC nanoparticles at low
(5mg/ml) concentration and high (20mg/ml)
concentration : Fu Chen, 2007
References:
1. Characterization of folate-chitosan-DNA nanoparticles for gene therapy Sania
Mansouria, Yan Cuieb, Francoise Winnikb
2. Preparation and characterization of protein-loaded N-trimethyl chitosan
nanoparticles as nasal delivery system Maryam Amidi, Stefan G. Romeijn
3. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl
chitosan and a cisplatin–alginate complex S. Cafaggi, E. Russo, R. Stefani
4. Preparation and modification of N-(2-hydroxyl) propyl-3-trimethyl ammonium
chitosan chloride nanoparticle as a protein carrier Yongmei Xu, Yumin Du
5. Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as
protein carriers Fu Chen, Zhi-Rong Zhang
6. Chitosan nanoparticle as protein delivery carrier - Systematicexamination of
fabrication conditions for efficient loading and release Quan Gan, Tao Wang
7. Chitosan nanoparticles as delivery systems for doxorubicin Kevin A. Janes,
Marie P. Fresneau
8. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel
Jong-Ho Kim, Yoo-Shin Kim, Sungwon Kim
9. Microencapsulated chitosan nanoparticles for lung protein delivery Ana Grenha,
Begona Seijo
10. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein
delivery Fu Chen, Zhi-Rong Zhang, Fang Yuan